Dual B-cell targeting therapy ameliorates autoimmune cholangitis

Area of Science:

• Immunology
• Autoimmune Diseases
• Hepatology

Background:

• B cell regulation holds therapeutic promise for autoimmune diseases like primary biliary cholangitis (PBC).
• Previous B cell-targeted therapies for PBC have yielded disappointing results, with Rituximab treatment associated with elevated B-cell activating factor (BAFF) levels.
• Current PBC therapies focus on bile salt modulation rather than effector pathways.

Purpose of the Study:

• To investigate the therapeutic potential of targeting long-lived memory B cells and short-lived peripheral autoreactive plasma cells in PBC.
• To evaluate the efficacy of anti-BAFF and anti-CD20 monoclonal antibodies, individually and in combination, in a murine model of PBC.

Main Methods:

• Administration of anti-BAFF and anti-CD20 monoclonal antibodies to ARE-Del mice, a model for human PBC.
• Comparison of therapeutic efficacy of individual agents versus combination therapy in female mice with established disease.

Main Results:

• Combination therapy significantly enhanced B cell depletion, leading to more effective clinical and serologic responses compared to individual agents.
• Combined anti-BAFF and anti-CD20 treatment reduced serum levels of antimitochondrial antibody (AMA), IgM, and IgG more effectively than monotherapy.
• A unique IgM+ FCRL5+ B cell subset sensitive to dual therapy was identified, and its depletion correlated with reduced liver pathology.

Conclusions:

• Dual B cell targeting therapy with anti-BAFF and anti-CD20 demonstrates significant clinical improvement and efficient B cell depletion in a PBC mouse model.
• This combination therapy shows potential for treating PBC patients, particularly those with incomplete responses to conventional treatments.
• Further studies in diverse PBC animal models are warranted before human clinical trials can be considered.